AADI - Aadi Bioscience Published Long-Term FYARRO Efficacy and Safety Data for the Treatment of Malignant PEComa

2024-03-04 06:43:57 ET

DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Aadi Bioscience, Inc. (NASDAQ: AADI ) announced, in late Friday trading, that it published the long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab -sirolimus in malignant PEComa in the Journal of Clinical Oncology (JCO) , in a manuscript titled, “A Phase 2 Trial of nab -Sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-term Efficacy and Safety Update,” authored by Andrew J. Wagner, MD, PhD and colleagues.

Aadi is trading at $2.24, up $0.32 (+16.67%), on trading volume of 329K shares.

The AMPECT trial confirmed, after 3 years of follow-up, clinically meaningful overall response rate, including multiple patients with complete responses

“We are excited to report the final outcomes of this registrational trial after an additional 3 years of follow-up. Responses to nab -sirolimus in patients with advanced PEComa lasted a median of 39.7 months,” commented Dr. Wagner, Senior Physician at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. “The median survival outcomes were consistent with the primary analysis, and the confirmed overall response rate remained at 38.7% and included an additional patient with a complete response. The long-term, durable responses to nab -sirolimus with tolerable safety are great news for patients with this rare disease.”

“The data published in JCO highlight the potential for nab -sirolimus to be an effective and highly differentiated treatment that may help patients suffering from this aggressive cancer achieve longer duration of responses and survival rates,” said Loretta Itri, MD, Chief Medical Officer of Aadi. “We want to thank the principal investigators, study coordinators, and the patients who participated in AMPECT. We believe these results provide a significant contribution to sarcoma research and we look forward to continuing to advance nab -sirolimus.”

The post Aadi Bioscience Published Long-Term FYARRO Efficacy and Safety Data for the Treatment of Malignant PEComa appeared first on 24/7 MarketNews .

For further details see: